036220.Kq

The company maintains a relatively strong liquidity position, with a current ratio of 4.22, indicating that it has sufficient current assets to cover its current liabilities multiple times over. However, the company's free cash flow is negative at -15.32 billion KRW, which suggests that it is currently spending more on capital expenditures than it is generating in operating cash flow. The company's cash and equivalents amount to 21.59 billion KRW, but this is less than its long-term debt of 44.31 billion KRW, resulting in a net cash position that is negative after subtracting total debt.

In terms of profitability, the company's return on equity (ROE) is 1.11%, and its return on assets (ROA) is 0.92%, both of which are below the industry median for the healthcare equipment and supplies sector. The company's operating margin is 8.05%, which is also below the industry median, indicating that it is less efficient in converting revenue into operating profit compared to its peers. The company's debt-to-equity ratio is 0.16, which is relatively low and suggests a conservative capital structure.

The company's revenue is concentrated in a single business segment, as disclosed in its latest financial report, with no significant geographic diversification mentioned in the available data. This lack of diversification may expose the company to higher risk if demand in its primary market or product line declines. The company's revenue concentration is a key factor in its risk profile, as it does not appear to have multiple revenue streams to buffer against market volatility.

Looking ahead, the company's revenue is expected to grow in the current fiscal year, with a projected increase in revenue driven by expansion in its core product lines and market share gains. However, the company's free cash flow is expected to remain negative in the near term due to ongoing capital expenditures, which may limit its ability to return value to shareholders through dividends or share repurchases. The company's capital expenditure of 19.01 billion KRW in the latest reporting period indicates a significant investment in its operations, which could support long-term growth but may also strain short-term liquidity.

The company's risk assessment highlights a medium liquidity risk, primarily due to its negative free cash flow and the fact that its cash and equivalents are less than its long-term debt. The risk of dilution is currently low, as the company has not issued additional shares recently, and there is no indication of a pending equity offering or other dilutive event. However, the company's capital structure and ongoing capital expenditures could lead to future dilution if it needs to raise additional capital to fund its operations or expansion plans.

Recent filings and transcripts indicate that the company is focused on expanding its product portfolio and improving operational efficiency to drive growth. The company has also emphasized the importance of maintaining a strong balance sheet and managing its debt levels to ensure long-term financial stability. These strategic priorities suggest that the company is aware of its financial challenges and is taking steps to address them, which could improve its financial performance and risk profile over time.